IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 94.6% during the fourth quarter, HoldingsChannel reports. The fund owned 1,160 shares of the medical research company’s stock after selling 20,452 shares during the period. iA Global Asset Management Inc.’s holdings in IQVIA were worth $228,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Synergy Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at $60,000. Finally, UMB Bank n.a. grew its holdings in IQVIA by 72.8% in the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 169 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IQV. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

Shares of NYSE IQV opened at $185.85 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.54. The business has a 50 day moving average price of $194.94 and a two-hundred day moving average price of $208.45. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.